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Entorhinal cortexStudies of individualswith amnesticmild cognitive impairment (aMCI) have detected hyperactivity in the hippo-
campus during task-related functional magnetic resonance imaging (fMRI). Such elevated activation has been
localized to the hippocampal dentate gyrus/CA3 (DG/CA3) during performance of a task designed to detect the
computational contributions of those hippocampal circuits to episodic memory. The current investigation was
conducted to test the hypothesis that greater hippocampal activation in aMCI represents a dysfunctional shift
in the normal computational balance of the DG/CA3 regions, augmenting CA3-driven pattern completion at
the expense of pattern separationmediated by thedentate gyrus.We tested this hypothesis using an intervention
based on animal research demonstrating a beneﬁcial effect on cognition by reducing excess hippocampal neural
activity with low doses of the atypical anti-epileptic levetiracetam. In a within-subject design we assessed the
effects of levetiracetam in three cohorts of aMCI participants, each receiving a different dose of levetiracetam.
Elevated activation in the DG/CA3 region, together with impaired task performance, was detected in each
aMCI cohort relative to an aged control group. We observed signiﬁcant improvement in memory task perfor-
mance under drug treatment relative to placebo in the aMCI cohorts at the 62.5 and 125 mg BID doses of leveti-
racetam. Drug treatment in those cohorts increased accuracy dependent on pattern separation processes and
reduced errors attributable to an over-riding effect of pattern completion while normalizing fMRI activation in
the DG/CA3 and entorhinal cortex. Similar to ﬁndings in animal studies, higher dosing at 250 mg BID had no
signiﬁcant beneﬁt on either task performance or fMRI activation. Consistent with predictions based on the com-
putational functions of the DG/CA3 elucidated in basic animal research, these data support a dysfunctional
encoding mechanism detected by fMRI in individuals with aMCI and therapeutic intervention using fMRI to
detect target engagement in response to treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A longstanding computational theory attributes successful memory
to a balance between two complementary functions mediated by the
hippocampal dentate gyrus and CA3 regions, which receive input from
layer II neurons of the entorhinal cortex. The model proposes that pat-
tern separation, a function ascribed to the granule cells of the dentate
gyrus, reduces mnemonic interference by encoding distinctive repre-
sentations for similar input patterns, while pattern completion refers
to the recovery of a prior representation from partial or degradedand Behavioral Sciences, Johns
eet/Phipps 300, Baltimore, MD
6.
. This is an open access article underinput, a function ascribed to the extensive recurrent collaterals of CA3
neurons (McClelland et al., 1995; Norman and O3Reilly, 2003; O3Reilly
and McClelland, 1994; Treves and Rolls, 1994); for a review see Yassa
and Stark (2011). It has been proposed that such competing, yet com-
plementary processes would minimize interference while maximizing
storage capacity for episodic memories. Empirical evidence consistent
with this model is supported by studies of the encoding properties of
neurons in these brain regions in laboratory animals (Alme et al.,
2014; Lee et al., 2004; Leutgeb et al., 2004; Neunuebel and Knierim,
2014). High-resolution functional magnetic resonance imaging (fMRI)
has also demonstrated alterations in fMRI activation in the DG/CA3 re-
gions consistent with such computational functions in the human
brain (Bakker et al., 2008; Yassa et al., 2010, 2011a).
In elderly human subjects (compared to young adults) and in pa-
tients with aMCI (compared to age-matched controls), increased fMRIthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2011a), using a three-judgment memory task designed to tax pattern
separation. In both cases, increased activity was correlated with worse
memory performance. Moreover, this conditionwas associatedwith re-
duced pattern separation and a shift to errors indicative of pattern com-
pletion. Based on theseﬁndings,we conducted a randomized controlled
trial (RCT) of the functional signiﬁcance of excess fMRI activation and its
contribution to cognitive impairment in aMCI subjects, using levetirac-
etam, an atypical anti-epileptic. We demonstrated that reduction of
DG/CA3 BOLD overactivity, resulting from levetiracetam treatment, im-
proved performance of the aMCI subjects on the 3-judgment memory
scanning task (Bakker et al., 2012). The full RCT enrolled three cohorts
of aMCI patients who were treated with levetiracetam in a range of low
doses and evaluated on the 3-judgment memory task designed to assess
pattern separation/completion processes. Here we report the ﬁndings
from the full dose-ﬁnding study. The study focused on the network com-
ponents most affected in the animal models, particularly subregions of
the hippocampal formation and the entorhinal cortex. Consistent with
those models, we reliably observed elevated fMRI BOLD activation local-
ized to the DG/CA3 subregion of the hippocampal formation, together
with a consistent proﬁle in memory performance showing a shift in bias
away from pattern separation in favor of pattern completion across
aMCI cohorts. At doses of levetiracetam that improved memory perfor-
mance in the scanning task, drug treatment also normalized fMRI activa-
tion in both the entorhinal cortex and DG/CA3 region, reducing DG/CA3
fMRI activity and boosting decreased fMRI activation in the entorhinal
cortex (EC). Those ﬁndings are consistent with the close coupling across
animal and human data in aging and prodromal Alzheimer3s disease,
with growing interest in the role of neural hyperactivity as a potential
therapeutic target to restore the network properties of circuits that are
among the earliest affected in Alzheimer3s disease (Stargardt et al., 2015).
2. Methods
2.1. Study design
The design for this study is schematically shown in Fig. 1. The entire
RCT protocol consisted of 4 study visits over an 8-week period. Each co-
hort of aMCI participants was randomized, double-blind, in a within-
subject crossover design,with the order of treatment ondrug andplacebo
counterbalanced within each cohort. Age-matched controls were treated
single-blind on placebo as further described in the procedures that follow.
2.2. Participants and clinical characterization
During the baseline visit all participants completed the dementia
rating scale (CDR: Morris, 1993), and underwent medical, psychiatric,Fig. 1. Schematic of tneurological and neuropsychological evaluations, which included the
Mini Mental Status Exam (Folstein et al., 1975), the Buschke Selective
Reminding Test (Buschke and Fuld, 1974), the Verbal Paired Associated
subtest of theWechslerMemory Scale (Wechsler, 1987) and the Benton
Visual Retention Test (Benton, 1974). All aMCI participants had a global
CDR score of 0.5 with a sum of boxes score not exceeding 2.5 and met
criteria for aMCI proposed by Petersen (Petersen, 2004), which includes
impaired memory function on testing and no decline in basic activities
of daily living. All control subjects had a global CDR score of 0. None of
the aMCI participants or age-matched control subjects met criteria for
dementia. Other exclusion criteria included major neurological and
psychiatric disorders, head trauma with loss of consciousness, history
of substance abuse or dependency, and general contraindications to
having an MRI examination (e.g. cardiac pacemaker, aneurysm coils
and claustrophobia) or taking the study medication (e.g. known sensi-
tivity or allergies, or severe renal impairment). Participants taking
anti-epileptic medications were excluded from participation in the
study but use of other neuroactive medications was permitted if the
participant was stable on the medication for at least 12 weeks and if
the treatment regimen was not altered for the duration of the study.
The study protocol was approved by the Institutional Review Board of
the Johns Hopkins Medical Institutions. All participants provided writ-
ten informed consent and were paid for their participation in the study.
At the baseline evaluation sixty-nine participants with aMCI and 24
age-matched controls met criteria for enrollment. Complete data from
54 participants with aMCI and 17 control participants were included
in the analysis. Nine aMCI participants and 6 control participants did
not complete the study protocol. Data from an additional 6 aMCI partic-
ipants and 1 control participant were excluded before analysis due to
excessive motion or in-scanner task performance that was inadequate
for analysis of the fMRI data.
2.3. Study procedures
All participants completed the same study procedures with fMRI
study visits after each of two treatment phases, separated by a washout
period of 4 weeks as shown in Fig. 1. Control subjects were given place-
bo during both treatment phases (single-blind) while participants with
aMCI were given placebo during one treatment phase and drug during
the other treatment phase,with the order of treatment counterbalanced
(randomized, double-blind). A ﬁrst cohort of aMCI participants received
treatment with 125 mg BID of levetiracetam (Keppra, UCB Laboratories),
as was previously reported (Bakker et al., 2012). Based on those initial
ﬁndings and earlier preclinical data in animals (Koh et al., 2010), two
additional doses were selected for two subsequent cohorts of aMCI
participants, receiving treatment with 62.5 mg BID and 250 mg BID of
levetiracetam, respectively. All study treatments (drug and placebo)he study design.
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Drug Service at Johns Hopkins Hospital. Capsules were provided in
blister packs labeled for morning and evening daily doses. After
2weeks on treatment, each study visit included a briefmedical and psy-
chiatric examination, the neuropsychological assessment, a blood draw
and an MRI scan during performance of the 3-judgment memory task.
At the end of the washout visit, each participant had a blood draw and
was provided with the study medication for the second treatment
phase of the study. Treatment compliance was assessed by participant
self-report at the end of each treatment phase, medication diaries, and
analysis of levetiracetam blood values at each visit during the study
protocol.
The study teamwas blind to the status of the aMCI participants and
levetiracetam blood levels until ﬁnal group analysis of the data. In
addition to providing the study medication the Investigational Drug
Service randomized aMCI participants to the treatment conditions and
controlled blinding and unblinding of study data according to standard
clinical trial procedures. Data safety was monitored by three physicians
not related to the study in collaboration with the Investigational Drug
Service.
2.4. fMRI activation paradigm
The fMRI activation paradigmwas a 3-alternative forced choice task
designed to assess pattern separation and completion processes, as
mentioned above (Bakker et al., 2012, 2008; Kirwan and Stark, 2007).
For this task participants were asked to view a series of stimuli
consisting of 768 pictures of common namable objects (see Fig. 2).
This included 96 pairs of related but not identical pictures of the same
object referred to as lures, 96 pairs in which the identical picture was
repeated, referred to as repeats and 384 unrelated single pictures of ob-
jects used as foils. Stimuli were divided over eight runs of 96 stimuli per
run. Each stimulus was presented for 2500 ms with a 500 ms inter-
stimulus-interval consisting of a blank screen. All trials were presented
in pseudo-random order with the limitation that a lure or repeated
stimulus was presented within 30 trials of its pair. For each stimulus,
the participant was asked to judge if the picture was ‘new’, ‘old’ or
‘similar’ but not identical. Stimuli were presented and responses col-
lected using an Apple Macintosh laptop computer running MATLAB
software (The Mathworks, Natick, MA), a back-projection screenFig. 2. Task designed to tax hippocampal DG/CA3 function. Participantswere shown a series of p
old (a repeated item) or similar (resembled a previously shown item). The lure items served aand an LCD projector located outside of the scan room. Participants
viewed stimuli via a mirror mounted on the head coil. Responses
were made using one button in the left hand and two buttons in
the right hand connected to a Cedrus RB-610 response box. Before
each MRI session subjects completed a brief practice task consisting
of 96 trials outside of the scanner to familiarize themselves with
the stimuli and the procedures.
2.5. MRI data acquisition
Imaging sessions were conducted on a 3 Tesla Philips scanner
(Philips, Eindhoven, The Netherlands) equipped with a SENSE paral-
lel imaging head coil (MRI Devices, Inc., Waukesha) and higher order
shims to compensate for local ﬁeld distortions at the F.M. Kirby Re-
search Center for Functional Brain Imaging at the Kennedy Krieger
Institute on the Johns Hopkins Medical Campus. High-resolution
functional images were collected using a T2*-weighted echo planar
single shot pulse sequence with an acquisition matrix of 64 × 64,
an echo time of 30 ms, a ﬂip angle of 70°, a sense factor of 2, an in
plane resolution of 1.5 × 1.5 mm and a TR of 1.5 s (Kirwan et al., 2007).
Each volume consisted of 19 oblique 1.5 mm thick axial slices with no
gap oriented along the principal axis of the hippocampus and covered
the medial temporal lobe bilaterally. Four dummy scans were completed
at the beginning of each run to allow for stabilization of the MR signal. In
addition, a whole brain structural scan was acquired using a magnetiza-
tion prepared rapid gradient echo (MPRAGE) T1-weighted sequence
with 231 oblique slices, 0.65 mm isotropic resolution and a ﬁeld of view
of 240.
2.6. fMRI data analysis
Image data analysis was performed using the Analysis of Functional
Neuroimages (AFNI) software package (Cox, 1996). The functional im-
ageswere ﬁrst co-registered to correct for slice timing and headmotion,
using a three-dimensional registration algorithm creating motion
vectors to remove trials in which a signiﬁcant head motion occurred
plus and minus one TR from further analysis. Of critical interest were
the participants3 responses on the ‘lure’ items used to assess the balance
between pattern separation and pattern completion functions in the
hippocampal formation. To avoid confusion, throughout the paper weictures of every day objects and asked to judge if the itemwas new (seen for theﬁrst time),
s the critical trials for assessing performance dependent on the dentate gyrus/CA3.
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targets’ and novel items subsequently tested with a similar lure as
‘subsequent lures’. The subsequent items all refer to the 1st presentation
trials. During the 2nd presentation, trials will be referred to as targets
and lures respectively.
Following this convention, functional runs were concatenated and 6
vectors were deﬁned tomodel the different trial types: (1) repeats sub-
sequently called “old”, (2) lures subsequently called “similar”, (3) lures
subsequently called “old”, (4) repeats called “old”, (5) lures called
“similar” and (6) lures called “old”. All other response types (misses,
false alarms, etc.) weremodeled but not included in the secondary anal-
yses. The full set of vectors were used to model each individual3s data
using a deconvolution approach based on general linear regression
treating the single foil presentations that were correctly rejected as a
non-zero baseline against which all other conditions were compared.
The resulting statistical ﬁt coefﬁcient maps represent the difference in
activity between each of the trial types and the baseline for a given
time point for a given voxel. The sum of the ﬁt coefﬁcients over the
length of the hemodynamic response (~3–12 s after the onset of the
trial) was taken as the model3s estimate of the response to each trial
type. The statistical maps were then smoothed using a Gaussian kernel
of 3 mm to account for variations in individual functional anatomy.
2.7. Cross-participant alignment
Methods used for cross-participant alignment in this study increase
the power of multi-subject regional fMRI studies by focusing the align-
ment power to the regions of interest using a segmentation of the
subject3s anatomical image. Initial afﬁne registration was used to trans-
form the subject3s anatomical and functional images to the Talairach
coordinate system (Talairach and Tournoux, 1988). Subregions of the
medial temporal lobe and the hippocampus were manually segmented
into three dimensions using the structural scan and methods described
previously (Bakker et al., 2008; Kirwan et al., 2007; Yassa and Stark,
2009). Brieﬂy, the entorhinal cortex, perirhinal cortex, parahippocampal
cortex, and temporopolar cortices were deﬁned bilaterally in the coronal
plane usingmethods described by Insausti et al. (1998). The CA1, DG/CA3
and subiculum subregions of the hippocampus were also deﬁned in the
coronal plane following landmarks described in the atlas of Duvernoy
(2005). The DG/CA3 region included the CA2/CA3/CA4 and dentate
gyrus subregions as these regions cannot be reliably separated on MRI
scans. Using both the segmentation label-based information for the
point-set expectation (PSE) error metric and the grayscale structural
image for the pure cross-correlation (PR) errormetric, AdvancedNormal-
ization Tools (ANTs)was used to calculate the 3Dvectorﬁeld transforma-
tion for each subject needed to align the individual3s ROIs to a template
modal model of the ROIs based on the entire sample (Klein et al., 2009;
Yushkevich et al., 2009) equally weighing the segmentations and T1
gray scale data. The 3D vector ﬁeld for each individual was then applied
to the concatenated ﬁt coefﬁcient maps resulting from the functional
analysis.
2.8. Statistical analysis
Age, education and neuropsychological and functional assess-
ment scores between groups were compared using independent
sample t-tests. The distribution of sex between groups was compared
using a chi-square test.
The primary objective of the study was to determine the efﬁcacy
of levetiracetam treatment in participants with aMCI, using within-
subject comparisons for each cohort. To facilitate a comparison of the
fMRI data across the three cohorts of aMCI participants, independent
analyses were ﬁrst conducted for each cohort using a two-way ANOVA
with trial type (6 trial type vectors) and group status (aMCI on placebo
and aged-matched control group) as ﬁxed factors and subject as a ran-
dom factor nested within group. A liberal voxel threshold of p b 0.07was used on the main effect of group F-statistic in combination with a
spatial extent threshold of 40 voxels to select areas of task-related activa-
tion. The resulting areas of activation were then combinedwith the ana-
tomical segmentations in order to include only voxelswithin our areas of
interest. The hybrid functional/anatomical analysis resulted in clusters of
voxels in each aMCI cohort where activity varied systematically between
aMCI and control cohorts within each of the anatomical regions of inter-
est. Voxels within each functional/anatomical region of interest were
then collapsed for further analysis. Planned comparisons using t-tests
were used for comparisons between the control and the aMCI cohorts
on placebo and for the comparisons within each aMCI cohort comparing
the aMCI participants onplacebo andon levetiracetamon the critical trial
type.
3. Results
3.1. Participants
The aMCI participants in each of the treatment cohorts did not signif-
icantly differ in age, education and proportion of males and females
from the subjects in the control group. Consistent with enrollment
criteria, participants with aMCI scored signiﬁcantly lower on immediate
and delayed recall on tests of verbal and visual memory (Table 1).
3.2. Increased DG/CA3 activation and impaired memory task performance
in participants with aMCI
In each of the three aMCI cohorts, an area localized in the left DG/
CA3 subregion of the hippocampus showed signiﬁcantly increased
BOLD activation during lure trials correctly identiﬁed as similar when
compared to control subjects (62.5 mg BID, t = 3.074, p = 0.004;
125 mg BID, t = −2.636, p = 0.013 and 250 mg BID, t = 2.070,
p = 0.047) (Fig. 3A–C). The aMCI participants in each cohort also
had a similar proﬁle in the 3-judgment memory task relative to
aged-matched controls as assessed by the rates of each response option
(old, similar, or new) on the critical lure trials. For those trials, a
between-groups ANOVA revealed a signiﬁcant effect of response type
and, importantly, a signiﬁcant group by response interaction in each co-
hort. A post-hoc analysis of that interaction by a planned contrast
showed that aMCI participants on placebo incorrectly identiﬁed lure
items as ‘old’ more often and gave relatively fewer correct responses
of ‘similar’ compared to control subjects (Control vs. aMCI placebo by
Old vs. Similar 62.5 mg BID, F(1,35) = 4.272, p = 0.046; 125 mg BID
F(1,32) = 7.687, p = 0.009; 250 mg BID F(1,32) = 9.167, p = 0.005)
(Fig. 3A–C). That proﬁle of fewer correct ‘similar’ responses is consistent
with reduced pattern separation and a shift to pattern completion,
e.g. more erroneous responses of ‘old’ in aMCI.
3.3. Levetiracetam treatment reduces DG/CA3 fMRI activation in aMCI and
improves memory function
To assess whether low dose levetiracetam treatment effectively re-
duces hippocampal activation, functional data during the fMRI memory
task performance in aMCI participants under placebo treatment was
compared with the data from those same participants under levetirace-
tam treatment. Theneuroanatomical regions of altered activity obtained
from the initial comparison of aMCI on placebo with the age-matched
control group for each of the three treatment cohorts were used to
assess the effects of levetiracetam treatment.
At the lowest dose, levetiracetam treatment using 62.5 mg BID did
not signiﬁcantly reduce BOLD activation compared to the placebo
condition (t = 1.417, p = 0.1726) during trials correctly identiﬁed as
similar. However, activation in the DG/CA3 subregion after levetirace-
tam treatment with 62.5 mg BID no longer differed from activity in
that region observed in the age-matched control group. Levetiracetam
treatment using 125 mg BID signiﬁcantly reduced BOLD activation
Table 1
Demographics and clinical characterization of healthy controls and aMCI participants.
Characteristic Controls aMCI 62.5 mg BID aMCI 125 mg BID aMCI 250 mg BID
Mean SD Mean SD p-Value Mean SD p-Value Mean SD p-Value
Subjects 17 20 − 17 − 17 −
Sex (M/F) 9/8 9/11 0.719 6/11 0.381 6/11 0.381
Age (years) 69.4 7.0 71.0 6.4 0.476 72.9 8.9 0.201 70.8 7.0 0.542
Education (years) 15.9 2.6 15.3 2.8 0.505 15.8 2.9 0.951 16.8 2.6 0.290
CDR 0 0.5 − 0.5 − 0.5 −
CDR sum of boxes 0.03 0.1 0.88 0.5 − 1.0 0.6 − 1.2 0.6 −
MMSE 27.9 1.5 26.5 2.5 0.048 25.7 2.3 0.002 25.9 2.5 0.007
LM delayed recall 29.5 5.2 17.8 9.4 b0.001 15.4 8.2 b0.001 22.9 7.7 0.006
BSRT delayed recall 7.7 1.9 4.5 2.9 b0.001 3.6 2.4 b0.001 3.4 2.1 b0.001
Wechsler VPA delayed recall 7.0 1.5 4.3 2.6 b0.001 3.9 2.9 b0.001 5.2 2.7 0.026
BVRT 5.8 1.8 4.9 1.6 0.091 4.5 1.5 0.026 5.2 1.7 0.338
CDR: Clinical Dementia Rating; MMSE: Mini Mental Status Exam; LM: Logical Memory Paragraph Recall; BSRT: Buschke Selective Reminding Test; VPA: Verbal Paired Associates; BVRT:
Benton Visual Retention Test. p-Values are based on independent sample t-tests comparing each aMCI cohort to the control group.
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those trials under placebo treatment (t = 2.279, p = 0.037). Levetirac-
etam treatment with 250 mg BID did not change activation during lure
trials correctly identiﬁed as similar relative to the activity during such
trials under placebo treatment (t= 0.326, p= 0.749) (Fig. 4A, C and E).
Treatment with low dose levetiracetam also improved behavioral
performance on the lure trials in treatment groupswhere levetiracetam
treatment normalized increased DG/CA3 activity. A post-hoc analysis of
the interaction by planned contrast showed that relative to their perfor-
mance on placebo, aMCI participants taking 62.5 mg BID or 125 mg BID
of levetiracetammade fewer incorrect responses of ‘old’while concom-
itantly increasing correct judgments of ‘similar’ (aMCI drug vs. aMCI pla-
cebo byOld vs. Similar; 62.5mgBID F(1,19)=4.783, p=0.041; 125mg
BID F(1,16) = 5.028, p = 0.039) and performance under drug treat-
ment in these groupswere no longer signiﬁcantly different fromhealthy
control subjects (aMCI drug vs. Control by Old vs. Similar; 62.5 mg BID
F(1,35) = 1.823, p = 0.186; 125 mg BID F(1,32) = 1.945, p = 0.173)
(Fig. 4B and D). Finally, in addition to not altering activation in the left
DG/CA3 during the critical lure trials, treatment with 250 mg BID of
levetiracetam also did not improve performance compared to their
performance on placebo. Relative to their performance on placebo
aMCI participants taking 250 mg BID of levetiracetam did not alter the
proportion of old and similar responses to lures (aMCI drug vs. aMCI
placebo by Old vs. Similar; F(1,16)= 1.492, p = 0.2396) and remained
signiﬁcantly different from control subjects (aMCI drug vs. Control by
Old vs. Similar; F(1,32) = 5.208, p = 0.029) (Fig. 4F).
To conﬁrm the ﬁnding that low dose levetiracetam treatment effec-
tively reduces hippocampal activation, a separate analysis was conduct-
ed inwhich voxel selectionwas based on a one-way ANOVA of trial type
only in control subjects. This analysis resulted in an area of task-related
activation similarly localized to the left DG/CA3 subregion of the hippo-
campus. The effect of drug treatmentwas conﬁrmed by comparing fMRI
activation in that area of task-related activity in aMCI participants on
placebo and levetiracetam within each of the three aMCI cohorts.
Conﬁrming the treatment effects shown in Fig. 4 this analysis similarly
showed that levetiracetam treatment using 62.5 mg BID lowered but
did not signiﬁcantly reduce BOLD activation compared to the placebo
condition (t = 1.503, p = 0.1492). Levetiracetam treatment using
125 mg BID signiﬁcantly reduced BOLD activation during the correctlyFig. 3. Increased hippocampal DG/CA3 activation is observed in the context of impaired memo
during the placebo condition in participants with aMCI in the (A) 62.5 mg BID treatment group
A–C: sagittal view of the left medial temporal lobe. Green vertical lines identify slices through t
interest including the CA1, dentate gyrus/CA3 (DG/CA3), and subiculum (SUB) subregions of th
related activity in the left DG/CA3 from anterior to posterior. Bottom left in A–C: mean activity
treatment groups show increased activity in the left DG/CA3 compared to healthy control subj
pants with aMCI on placebo in each of the treatment groups show impairedmemory performan
to healthy control subjects. Statistics show p-values resulting from a planned post-hoc contrast
means ± SEM. *p b 0.05.identiﬁed lure trials relative to the activity during those trials under
placebo treatment (t = 2.192, p = 0.044). Levetiracetam treatment
with 250mgBID, in contrast, showed noevidence of reducing activation
(t = 0.1773, p = 0.8615).
3.4. Levetiracetam treatment normalizes fMRI activation in the entorhinal
cortex in aMCI participants
In addition to areas of task related activity in the DG/CA3, analyses of
the functional imaging data also revealed an area of reduced task related
activity in the left entorhinal cortex (EC) in both the 62.5 mg BID cohort
and the 125 mg BID cohort. In the left entorhinal cortex, participants
with aMCI on placebo showed signiﬁcantly decreased BOLD activation
during those same lure trials compared to control subjects (62.5 mg
BID, t = 3.443, p = 0.002 and 125 mg BID, t = 3.278, p = 0.003). After
drug treatment BOLD activation in the left EC was increased and nor-
malized in aMCI participants during the critical lure trials in compari-
son to placebo treatment. This increase was statistically signiﬁcant in
the 62.5 mg BID cohort (t = 3.318, p = 0.004) but not statistically
signiﬁcant in the125mgBIDcohort (t=−1.60,p=0.129). Inbothco-
horts activity in the left EC after drug treatment was no longer differ-
ent from activity observed in the left EC in control subjects (Fig. 5).
3.5. Levetiracetam blood levels
These effects on BOLD activation in the left DG/CA3 and EC in the
62.5 mg BID and 125 mg BID treatment cohorts were obtained with
drug doses well below those used clinically for the treatment of epilepsy.
Drug levels in aMCI patients were determined to be 2.9 ± 0.29 µg/mL
(mean ± SEM) for the 62.5 mg BID cohort and 4.4 ± 0.53 µg/mL for
the 125 mg BID cohort. The ineffective dose of 250 mg BID provided a
drug level of 7.91 ± 0.92 µg/mL. These levels of drug exposure are well
below typical ranges for efﬁcacy of levetiracetam as an anti-epileptic
agent where doses of 1000–3000 mg/day are typical, achieving levels of
10–40 µg/mL (Lyseng-Williamson, 2011).
Consistentwith Bakker et al. (2012)measures of standard neuropsy-
chological test performance were not affected in any of the three treat-
ment cohorts.ry performance in three aMCI cohorts. Task related activation and behavioral performance
, (B) 125 mg BID treatment group and (C) 250 mg BID treatment group. (A–C) Top left in
he hippocampus shown to the right. Top middle in A–C: segmentation of the structures of
e hippocampus. Top right in A–C: coronal slices show statistical maps of the extent of task
during lure trials correctly called similar. Participants with aMCI on placebo in each of the
ects during lure trials based on independent samples t-tests. Bottom right in A–C: partici-
ce bymore often incorrectly judging lure items as “old” instead of similar when compared
for the interaction of group as a function of response type (old versus similar). Values are
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The primary focus in the current study was to assess the effects of
treatment with the atypical anti-epileptic, levetiracetam, on memory
performance in the scanning task and fMRI signals in aMCI patients.
In the current investigation, low doses of levetiracetam (62.5 and
125 mg BID) signiﬁcantly improved memory performance in the scan-
ning taskwith attenuation of overactivity, an effect that was statistically
signiﬁcant at 125 mg BID. In contrast, no difference in either memory
task performance or fMRI activation was observed at 250 mg BID. The
current ﬁndings further suggest that in the dose range of 62.5–125 mg
BID, levetiracetam confers beneﬁt on the network properties of the
medial temporal lobe memory system. In addition to excess fMRI
activation, a region of decreased activation in the entorhinal cortex
(EC) was observed during task performance, similar to Yassa et al.
(2010). While overactivity was attenuated by levetiracetam in aMCI
cohorts treated with low doses (62.5 and 125 mg BID), decreased EC
activation was concurrently normalized, with a signiﬁcant boost in EC
activation at the 62.5 mg BID dose compared to placebo.
The observed areas of fMRI activation, consistently localized to the left
DG/CA3 subregion in aMCI patients relative to age-matched controls, dif-
fered somewhat across cohorts in an anterior to posterior location. Al-
though differences in anterior–posterior localization have been
observed in neuroimaging studies using a variety of task-activated fMRI
paradigms, the functional signiﬁcance of such localization remains some-
what equivocal (see Poppenk et al., 2013 for review). Of possible rele-
vance in the current context Malykhin et al. (2010) noted a relatively
greater proportion of CA ﬁelds (CA1-3) in the anterior hippocampal for-
mation with the DG having a proportionately greater representation at
the posterior segments of the long axis. Overactivity in areas of
activation localized anterior to posterior, as reported here and elsewhere
(Bakker et al., 2012; Yassa et al., 2010) in the context of the 3-judgment
recognition task could reﬂect a relatively greater contribution of aug-
mented pattern completion in anterior areas of activationwith any excess
activation reﬂecting a loss of pattern separation in DG contributing more
in posterior areas of activation. Overall, however, these ﬁndings suggest
that excess fMRI activation in the DG/CA3 is associated with a consistent
proﬁle of memory task impairment across all three aMCI cohorts.
Importantly, no evidence was found in this study to support a bene-
ﬁcial compensatory role in cognition for excess hippocampal activation.
Instead, the data support the view that hippocampal overactivity
contributes to symptomatic impairment in the MCI phase of disease
(for review see Ewers et al., 2011). Because MCI patients with hippo-
campal overactivation also exhibit greater cortical thinning, which is in-
dicative of early Alzheimer3s disease (AD) related neurodegeneration
(Putcha et al., 2011), and excess hippocampal activation detected by
fMRI predicts subsequent cognitive decline (Miller et al., 2008), it is
hypothesized that hippocampal overactivity contributes to disease pro-
gression and neuronal damage if not controlled.
The deleterious effect of hippocampal overactivity detected by fMRI
is further supported by recent evidence of a distinctive gene expression
proﬁle underlying excessive hippocampal excitability inMCI patients. In
a study of autopsy brain samples, Berchtold et al. (2014) reported that
the mRNA microarrays from MCI brains exhibited a proﬁle that clus-
tered those patients together and segregated them from groups of
older controls and patients with a diagnosis of Alzheimer3s dementia.
In addition, mRNA markers for hippocampal excess excitability and
aberrant plasticity, whichwere hallmarks in theMCI proﬁle, were corre-
lated with severity of cognitive impairment within the MCI cohort. The
reliable signature of hippocampal overactivity in the current study for
three cohorts of aMCI patients aligns with such data, as does the detec-
tion of overactivity in the CA3/DG subregion reported in a separate
study of aMCI patients (Yassa et al., 2010).
Studies using neural recordings in rats ﬁrst focused attention on the
computational functions of the DG and CA3 regions as a basis for age-related memory impairment. Such studies in aged rats with memory
impairment have demonstrated a computational shift away from
pattern separation in the encoding properties of hippocampal neurons;
instead of the rapid encoding of new information, neurons retrieve a
previously encoded representation (Wilson et al., 2006, 2003). Likewise
in studies comparing young vs. older adults, the use of lures that are
similar, but not identical, in 3-judgment recognition demonstrates
that elderly participantsmake fewer correct responses of ‘similar’ indic-
ative of pattern separation, while increasing errors that reﬂect pattern
completion, e.g. judging lure items as ‘old’ repeats (Lacy et al., 2011;
Stark et al., 2013; Toner et al., 2009; Yassa et al., 2011b). Patients with
aMCI have shown further worsening in memory impairment on lure
items compared to age-matched controls (Stark et al., 2013; Yassa
et al., 2011b), as observed in the current investigation. Increased fMRI
activation in the DG/CA3 subregion in human aging (O3Brien et al.,
2010; Yassa et al., 2011a) and its further augmentation in aMCI, as re-
ported here and elsewhere (Bakker et al., 2012; Yassa et al., 2010),
may primarily reﬂect an elevation of CA3 neural activity which has
been directly observed in memory-impaired aged rats (Wilson et al.,
2005). Overactive CA3 neurons and their massive recurrent collaterals
are a likely a basis for driving greater pattern completion to shift the
balance away from pattern separation.
Although it is not possible to reliably differentiate DG apart fromCA3
in human brain imaging, any greater activation in the DG contributing
to the elevated fMRI signal in composite DG/CA3 areas of activation
could also reﬂect diminished pattern separation in the DG itself. In
addition to elevated activity in the ﬁring rates of CA3 pyramidal neu-
rons, another distinctive signature of aged memory-impaired rats is a
loss of integrity affecting the interneurons in the hilus (Spiegel et al.,
2013), which normally limits the activation of granule cells receiving
perforant path input from the EC (Andrews-Zwilling et al., 2010). In a
mouse model of genetic risk for Alzheimer3s disease, ApoE4 has been
observed to augment the age-dependent loss of hilar interneuron integ-
rity further reducing inhibitory control of DG granule cells (Andrews-
Zwilling et al., 2010). Although somewhat speculative, if a similar condi-
tion occurs in humans, a greater number of granule cells activated by
perforant path input could contribute to elevated fMRI activation in
DG/CA3 reﬂecting degradation of the sparse encoding by granule cells,
a property that is critical for pattern separation.
With respect to the EC, the currentﬁndings of decreased fMRI activa-
tion replicate that condition previously reported in aMCI patients com-
pared to age-matched controls (Yassa et al., 2010). Studies with animal
models have pointed to the EC as contributing to age-related memory
impairment and studies with humans have conﬁrmed the progressive
worsening of that impairment in patients with aMCI. Notably, in rats
the presence and severity of cognitive impairment in aging are tightly
coupled to loss of synaptic integrity for the layer 2 neurons in the EC
innervating DG and CA3 (Smith et al., 2000). In humans a further loss
of those connections is observed in MCI and AD compared to aging,
with that synaptic loss correlating with worse delayed-recall memory
performance (Scheff et al., 2006). Additionally, molecular alterations
affecting the EC layer 2 neurons occur in both age-related memory
impairment in rodents (Stranahan et al., 2011), as well as in AD animal
models (hAPP mice) and AD patients (Chin et al., 2007). Thus the
network comprised of the EC together with the hippocampal formation
exhibits features underlying age-related cognitive impairment that ex-
hibits a further progression in aMCI compared to aging. It should be
noted, however, that the current methods for detection of decreased
fMRI activation in the EC were not localized to a speciﬁc EC layer. The
fMRI signature in aMCI and its restoration by treatment could be
due to beneﬁcial effects on the network overall, involving not only EC
input to the hippocampus but also hippocampal output to the EC,
which innervates deeper EC layers. The relationship between loss of
EC input to the DG/CA3 and overactivity in those regions is also not
yet clearly deﬁned but could involve the extensive network of
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formance in aMCI participants by reducing errors in which lures were incorrectly judged “old”, with more correct judgments of “similar”. (C) In the 125 mg BID cohort levetiracetam signiﬁcantly reduced activation in the DG/CA3 and
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696 A. Bakker et al. / NeuroImage: Clinical 7 (2015) 688–698interneurons that receive EC andDG input to control excitability of prin-
cipal neurons in the DG/CA3 region.
The current investigation has served to identify a condition detected
by brain imaging and its modiﬁcation by an intervention built on basic
research that has increased our understanding of the contribution of cir-
cuits involving the EC and its targets in the DG and CA3 regions tomem-
ory. The current study leveraged discoveries in cognitive neuroscience
based on recordings of the encoding properties of neurons and use of
other methods not possible in humans. Studies in rodents, both youngadults and in a well-characterized model of neurocognitive aging,
were especially informative about the properties of the network under-
lying age-related memory impairment and initial preclinical tests of
therapeutic interventions (Koh et al., 2010, 2013; Wilson et al., 2006).
Low doses of the atypical anti-epileptic levetiracetam have shown ben-
eﬁt in conditions of age-related memory impairment in rodents and
laboratory models relevant to Alzheimer3s disease (Koh et al., 2010;
Rhinn et al., 2013; Sanchez et al., 2012; Shi et al., 2013; Suberbielle
et al., 2013). Levetiracetam has also been reported to have beneﬁcial
697A. Bakker et al. / NeuroImage: Clinical 7 (2015) 688–698effects in circuits throughout the MTL network when treatment im-
proves hippocampal-dependent cognition (Sanchez et al., 2012). More-
over, a therapeutic window for levetiracetam treatment similar to that
observed in the current clinical investigation has also been reported in
animal models (Koh et al., 2010; Sanchez et al., 2012; Shi et al., 2013),
with a lack of efﬁcacy for levetiracetam dosing in the usual clinical
range for treating patients with epilepsy (Koh et al., 2010; Sanchez
et al., 2012). Based on such ﬁndings, a translation from animal models
to humans with the use of brain imaging represents a promising
approach to advance discovery in clinical research.
The ﬁndings presented here result from a high-resolution approach
to deﬁning hippocampal subregions by imaging the medial temporal
lobe (MTL). As such the methods do not consider broader network
changes that have been observed in aging and MCI, for example in-
volving default mode networks in the cortex. Further research, in-
corporating both MTL high-resolution and whole brain acquisitions
in the same study population will make possible the assessment of
such changes as well as changes in connectivity with regions of task-
related fMRI in the MTL.
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